Moadel, Alyson B. PhD*; Bernstein, Steven L. MD†; Mermelstein, Robin J. PhD‡; Arnsten, Julia H. MD, MPH§; Dolce, Eileen H. PA‖; Shuter, Jonathan MD‖
Over half of persons living with human immunodeficiency virus (HIV; PLWH) in the United States smoke cigarettes.1,2 As longevity has improved secondary to effective antiretroviral therapy, alarming increases in the rates of tobacco-related illnesses including cancers3 and coronary events4 have been observed. Cigarette smoking is also associated with increased rates of opportunistic infections,5 poorer quality of life,6 and inferior medication adherence7 in PLWH. One large cohort study estimated that 24% of deaths in PLWH in the modern highly active antiretroviral therapy (HAART) era are attributable to the use of tobacco.8
As a group, PLWH smokers have high rates of substance use and comorbid psychiatric illness.9 They are exposed to a range of additional stressors including poverty,10 racism/discrimination,11 stigmatization,12 loneliness,12 and health concerns.13 These factors decrease the likelihood that brief, “simple” cessation interventions will be successful in HIV-infected smokers.14 High smoking rates among PLWH in New York, despite the frequency of advice to quit from providers, ready availability of quitlines and nicotine replacement therapy (NRT), and high motivation to quit attest to the fact that more intensive treatment options are necessary.2,9
There are few published randomized controlled trials of intensive cessation interventions for PLWH smokers.15–18 All of them employed one-on-one counseling strategies combined with an offer of NRT. Three of the studies demonstrated improved tobacco abstinence rates in recipients of the interventions.15–17 However, cessation programs targeting this group are uncommon, and there are no standard recommendations to guide providers and their patients in achieving and sustaining abstinence.
In 2008, with the input of HIV-care specialists, behavioral psychologists, tobacco treatment experts, and HIV-infected smokers, we developed Positively Smoke Free (PSF), an 8-session, group-therapy intervention based on social cognitive theory principles. PSF is an intervention specifically tailored to the HIV-infected population based on the patterns and predictors of tobacco use in PLWH.9 This article describes a randomized controlled trial of PSF involving a group of HIV-infected smokers in the Bronx, New York. We hypothesized that participants in the PSF intervention would achieve higher abstinence rates than those in a standard care treatment group.
Research Setting and Project Staff
Montefiore Medical Center is a 1491-bed teaching hospital located in the Bronx. Its Infectious Diseases Clinic provides care to over 2700 HIV-infected adults, the majority of whom belong to ethnic minority groups and have incomes below the federal poverty line. The group leaders for PSF consisted of 2 “professional” and peer-facilitator pairs recruited from the Ferkauf Graduate School of Psychology and the ID Clinic patient roster, respectively. All group leaders were ex-smokers, and the 2 peers were HIV infected. Before conducting any sessions, all of them completed certified courses in tobacco treatment.
This was a prospective randomized controlled study comparing the PSF program and offer of NRT to standard of care (including offer of NRT). The patients were referred by their clinic providers or recruited from the waiting room. The participants completed self-report questionnaires on days 0, 42, and 132, and exhaled carbon monoxide (ECO) measurement. The primary endpoint was 7-day self-reported, point-prevalence abstinence at the final study visit (∼3 months post quit date). The subjects reporting abstinence with discrepant ECO levels of ≥10 ppm were coded as nonabstinent.
Individuals expressing interest in the study were screened for eligibility by confirming their HIV infection status (with either a positive enzyme immunoassay or a detectable HIV-1 viral load), smoking status (with an affirmative response to “During the past 5 days, did you use any product containing nicotine including cigarettes, pipes, or cigars?”19), and motivation to quit (by scoring ≥6 on the Readiness to Quit Ladder20). The subjects who provided consent were randomized in a 1:1 schedule to the 2 study conditions.
The Standard Care Condition
The subjects were given a quit smoking brochure, brief advice to quit (ie, <5 minutes), and an offer of a 3-month supply of NRT.
The Positively Smoke Free Condition
The subjects were assigned to either a day or evening program group, according to their preference. The study staff aimed to enroll between 6 and 8 subjects to each group. The program emphasized the use of a buddy, a supportive friend or family member, to provide encouragement through the quit attempt. The buddies were welcome to attend the sessions. Travel fare was provided to each attendee, including buddies.
PSF is an 8-session intervention modeled after the program described in the Tobacco Dependence Treatment Handbook14 and based on Social Cognitive Theory principles.21 Its content was crafted to address numerous concerns of particular relevance to PLWH smokers (eg, specific risks of smoking to PLWH, comorbid psychiatric illness and substance use, social isolation, stress reduction) that were identified in our preliminary work,9 and it was revised and refined through multiple pilot offerings. An overview of the course curriculum, including HIV-referent themes, is presented in Table 1. Each session is led by 2 cofacilitators (a “professional” and a peer) and encourages the recounting of personal experiences and a group interaction dynamic. The same cofacilitators remain with a given group throughout all the sessions. Sessions are 90 minutes long and occur weekly, except for the session after Quit Day (session 5), which is scheduled 3 days after the quit. At the first session, Quit Day is defined as the day on which all tobacco use will cease and is planned for the entire group 4 weeks thereafter.
All the participants were asked to complete a self-administered, pencil-and-paper questionnaire at the 3 study visits. Tobacco use and tobacco knowledge was assessed with questions from the CDC QIT Inventory.19 Nicotine addiction was assessed with the Modified Fagerstrom Tolerance Questionnaire.22 Motivation to quit was assessed with the Abrams and Biener Readiness to Quit Ladder.20 Reasons for quitting were assessed with the Reasons for Quitting Scale, which measures intrinsic (concerns about health, desire for self-control) and extrinsic (immediate reinforcement, social influence) motivation for smoking cessation.23 Self-concept was assessed with the Smoker Self-concept and Abstainer Self-concept Questionnaire, which measures the extent to which smokers perceive themselves as more similar to smokers or abstainers.24 Self-efficacy was assessed with the Self-efficacy/Temptations Scale, which measures the level of confidence to abstain from smoking in positive affect/social situations, negative affect situations, and habit/craving situations.25 Decisional balance was assessed with the Smoking Decisional Balance Short Form, which measures perceived pros and cons of smoking.26 Social support was assessed with the Partner Interaction Questionnaire, which measures level of predicted support from a significant other for one's cessation efforts.27 Spirituality was assessed with the Ironson-Woods Spirituality Index, which measures sense of peace, faith in a deity, religious behavior, and compassion for others.28 Loneliness was assessed with the UCLA Loneliness Scale.29 Depression and anxiety were assessed with the Center for Epidemiologic Studies Depression Scale30 and the State-Trait Anxiety Scale.31 Abstinence was assessed using a question from the CDC QIT Inventory,19 “Now, think carefully about the last 7 days. Did you smoke cigarettes, even a puff, on any of those days?” Exhaled carbon monoxide (ECO) levels were measured using the Bedfont piCO+ Smokerlyzer (Bedfont Scientific Ltd, Kent, United Kingdom) maintained according to the manufacturer's instructions.
All the sessions were recorded. Fifty-eight percent of the sessions were reviewed by the graduate student who was not leading the group, and topic coverage checklists were completed for each session. Checklists included a mean of 11 items per session, which could be scored as “Yes” or “No” for coverage during the session.
Study Contamination Survey
Control subjects were asked a series of questions inquiring about discussion of program contents with intervention condition subjects and also inquiring about familiarity with specific cessation strategies (eg, deep-breathing techniques) taught in PSF.
Program Satisfaction Survey
PSF subjects rated the various components of the program on a Likert scale ranging from “not helpful at all” to “extremely helpful.”
Sample Size Considerations
Based on the 2 studies of PLWH smokers available at the time,15,16 the investigators estimated that 25% of the PSF group and 8% of the control group would achieve the primary cessation endpoint. A sample size of 148 subjects was predicted to provide 80% power to detect a significant difference in the study outcome between the 2 conditions with a null hypothesis of no difference in outcome between groups.
Dichotomous variables were analyzed using χ2 or Fisher exact test. Comparisons of means were accomplished using Student t-test or Mann–Whitney U-test. Correlation of 2 continuous variables was performed using Spearman rank correlation. In evaluating factors associated with the abstinence outcome, a backward, stepwise multivariate logistic regression analysis was performed incorporating those variables that were associated (P ≤ 0.10) with abstinence on univariate analysis. Because this was an efficacy trial of PSF, study condition was included in all multivariate models regardless of its level of association on univariate analyses. A mixed-effects linear modeling approach was used to assess the association of study condition with variables repeatedly measured during the 3 study visits. Changes from assessment 1 to assessment 3 were calculated for those variables found to be significantly associated with study condition in the mixed-effects linear modeling analyses, and the new variables, reflecting the change in these variables, were individually added into the logistic regression models to assess for independence of association with abstinence and also for mediating effects. Substantial attenuation of the association between study condition and the abstinence outcome after inclusion of one of these covariates was interpreted as a mediating effect of the variable on the study condition-abstinence relationship. Data analyses were performed using SPSS version 18.0 or SAS version 9.13.
The study was reviewed and approved by the Montefiore Medical Center Institutional Review Board.
A total of 184 individuals were screened for entry into the study. Thirty-seven were excluded because of: failure to return for the enrollment visit (17), uncertain smoking status with ECO in nonsmoker range (7), low motivation to quit score (6), scheduling conflicts (3), decision to try to quit outside of the study setting (2), and successful cessation before enrollment (2). Of the 147 subjects who enrolled in the study, 2 were discovered to be ineligible before randomization, yielding a final sample of 145. Seventy-three were randomized to PSF and 72 to the control condition. One hundred thirty-nine subjects (95.9%) completed the study (Fig. 1). For analytic purposes, the subjects who were lost to-follow-up were considered nonabstinent.
The participants ranged in age from 29 to 70 years with a mean of 48.6 ± 7.0. Forty-nine percent of the cohort were male, 50.3% were female, and 0.7% were transgender, 85.8% were Black/African American, 11.0% were White, and 3.1% were American Indian/Alaskan Native. Across races, the study sample was 22.8% Latino. The HIV risk behavior was heterosexual contact in 57.9%, same-sex contact in 14.5%, injection drug use in 9.0%, transfusion in 2.8%, and unknown in 15.9%. Less than a quarter (23.3%) were married or living with a partner, and 88.0% were unemployed. Recent (within the past 30 days) use of marijuana was reported by 41.7%, cocaine by 28.9%, and heroin by 7.6%. Mean of the cohort's most recent CD4+ count was 494 ± 289 cells per microliter (range: 5–1681). Mean duration of cigarette smoking experience for the cohort was 32.7 ± 8.2 years (range: 11.0–54.0), and mean daily cigarette intake was 12.0 ± 8.8 (range: 1–60). Mean score at enrollment on the Fagerstrom Tolerance Questionnaire was 5.0 ± 2.1 with 24.8% scoring ≥7, indicating high nicotine dependence. There were no differences in baseline characteristics between the 2 conditions (Table 2).
Twenty-one (14.5%) subjects achieved the primary cessation outcome, including 14/73 (19.2%) from the PSF group and 7/72 (9.7%) from the control group. Nine additional subjects (5 from PSF) had discrepant ECO results and were classified as nonabstinent. The difference in proportions of subjects achieving the primary study endpoint between the 2 conditions did not achieve statistical significance [odds ratio, OR = 1.97 (0.85–4.60), P = 0.11]. Factors that were significantly associated with the cessation outcome on univariate analysis included older age (P = 0.03), Latino ethnicity (P = 0.04), and higher self-efficacy on the Positive Affect/Social Situations subscale (P = 0.02), lower score on the decisional balance Pro subscale (P = 0.02), and lower loneliness score (P = 0.01). On multivariate analysis (Table 3), factors that were independently associated with the cessation outcome were Latino ethnicity and loneliness score. None of the other sociodemographic, clinical, or psychometric measures recorded were significantly associated with the cessation outcome. There was no significant difference in outcome between the 2 different pairs of group leaders. Fifty-eight subjects (40%) received either NRT, bupropion, or varenicline, during the course of the study, and their quit rate (15.5%) did not differ from those who did not receive pharmacotherapy (13.8%). Subjects with high nicotine dependence scores (≥7) were more likely to receive NRT [OR = 2.39 (1.06—5.38), P = 0.03], but receipt of NRT was not associated with a difference in quit rates according to study condition in this subset of participants. Although the proportion of pharmacotherapy recipients in the PSF condition exceeded that of the control condition (46.6% vs. 33%) the difference was not statistically significant (P = 0.10).
Complete-Case, As-Treated Analysis
Complete-case, as-treated analyses were performed excluding the 6 losses to follow-up and 10 subjects in the PSF condition who failed to attend any of the sessions (3 subjects met both of these criteria), yielding a cohort of 132 subjects. In these analyses, subjects assigned to PSF were significantly more likely to achieve the cessation endpoint on both univariate [OR 2.63 (0.98–7.01), P = 0.05] and multivariate [ORadj 3.55 (1.04–12.0), P = 0.04] analyses. Additional factors that were independently associated with abstinence included white race, lower decisional balance Pros score, and lower loneliness score (Table 4).
Repeated Measures Analysis
Repeated measures analyses assessed the effect of PSF over time on the behavioral and psychometric measures. In these analyses, assignment to the PSF condition was associated with increased global self-efficacy (P = 0.01), increased Positive Affect/Social Situations self-efficacy (P = 0.006), increased Habit/Craving Situations self-efficacy (P = 0.04), increased Negative Affect Situations self-efficacy (P = 0.04), increased motivation to quit (P = 0.003), and a greater reduction in daily cigarette consumption (P = 0.002). When only nonabstinent subjects were considered, there was a significantly greater reduction in cigarettes smoked per day in the PSF condition compared with controls (−6.6 vs. −2.6 cigarettes per day, P = 0.02).
The change in score from visit 1 to visit 3 was calculated for the 2 behavioral measures that were most significantly associated with the PSF condition on repeated measures analysis (Positive Affect/Social Situations self-efficacy and motivation to quit). These new variables were entered, individually, into the intention-to-treat logistic regression model. In these analyses, change in Positive Affect/Social Situations self-efficacy was independently associated with abstinence [ORadj = 3.17 (95% confidence interval, CI: 1.50 to 6.67), P = 0.002] with concurrent attenuation of the association of study condition with the abstinence [ORadj = 1.56 (95% CI: 0.44 to 5.49), P = 0.49]. Change in motivation to quit was neither associated with the outcome variable nor did it attenuate the association of study condition with the outcome variable. These findings suggest that the effect of PSF on the abstinence outcome was at least partially mediated by a change in Positive Affect/Social Situations self-efficacy.
Intervention-Outcome Dose–Response Relationship
PSF condition subjects attended a mean of 4.0 ± 2.6 sessions. Older age was correlated with a higher number of sessions attended (Spearman rho = 0.24, P = 0.04), but gender, ethnicity, race, and baseline motivation to quit were not. Fourteen subjects (19.2%) attended ≥7 sessions. There was an upward inflection in abstinence associated with attending ≥7 sessions (42.9% abstinent), compared with those attending <7 sessions (13.6% abstinent), OR = 4.78 (1.31–17.4), P = 0.01. Although the receipt of pharmacotherapy did not seem to affect abstinence rates in the remainder of the cohort, of the 8 subjects who attended ≥7 sessions and received pharmacotherapy, 5 (62.5%) achieved the abstinence outcome.
Overall fidelity to the program curriculum in the 7 group-therapy cycles audited was 87.4% ± 5.1%.
Among the control condition subjects, 5.7% reported having discussed PSF activities with PSF condition subjects, and 10.0%–17.1% reported familiarity with cessation strategies presented in the program sessions. There were no significant differences in abstinence rates in control subjects responding affirmatively to the study contamination survey questions as compared with those responding negatively.
Program elements that were rated most helpful by the participants were, in order, “Sharing with and hearing from group members,” “Sharing the experience with a group of smokers living with HIV,” “The parts of the sessions that were about living with HIV,” and “Having a group leader who is living with HIV.” The elements that were rated the least helpful were “Role playing during the sessions,” “Weekly homework assignments,” and “Learning how to work with a buddy.”
This study reports the results of a tailored group intervention for tobacco use in PLWH. We enrolled 145 subjects into a randomized controlled trial of an intensive group intervention targeting HIV-infected smokers who were motivated to quit. Its emphasis was on building self-efficacy to quit and to remain abstinent. Its curriculum was crafted to address issues of particular importance to PLWH as determined in earlier work published by ourselves and others.9,13 To strengthen the personal relevance of the course content, one of the group coleaders was an HIV-infected ex-smoker.
The outcomes observed in this study show promise. Abstinence rates in those assigned to the PSF condition were almost double those of the control condition. The 19.2% 3-month abstinence rate in the PSF group compares favorably with the other published trials of intensive interventions in PLWH smokers.16–18 Although the increased abstinence rate that we report did not achieve statistical significance in the primary analysis, several findings suggest that PSF was effective in achieving its aims. A cessation rate of 19.2% in this challenging population compares very favorably with a mean cessation rate of 13.9% (11.6%–16.1%) derived from meta-analysis of group counseling interventions conducted in other settings.32 In the complete-case, as-treated analysis, the difference in the abstinence rates between the 2 conditions was statistically significant. Reduction in daily cigarette consumption was significantly greater in PSF subjects. Finally, we were able to demonstrate a significant advantage for PSF condition subjects over controls in changes on all measures of self-efficacy, the behavioral domain that was most specifically targeted by the program curriculum, and additional post hoc analyses suggested that change in Positive Affect/Social Situations self-efficacy mediated the effect of PSF on the abstinence outcome.
Retention is a frequent challenge in multisession behavioral interventions. In a study of the program that provided the model for our curriculum, the subjects attended a mean of 5.9 out of 8 sessions.33 The mean and median number of sessions attended in the PSF condition was 4, with only 5 subjects completing all 8 sessions. Quit rates were significantly higher in those who attended ≥7 sessions, especially if they received pharmacotherapy. This suggests that strategies to improve the efficacy of intensive group therapy in the future should include efforts to maximize attendance and pharmacotherapy acceptance among the participants.
The data that we present on correlates of successful cessation may also be instructive in the development of future interventions. Our findings and those of others18,34 suggest that African American PLWH smokers may face special challenges. The 3 psychobehavioral domains found to be associated with the abstinence outcome in our study were self-efficacy, decisional balance, and loneliness. Self-efficacy, or confidence in oneself to resist the temptation to smoke, is a critical determinant of successful cessation.25 The Positive Affect/Social Situations subscale (ie, confidence in oneself to resist smoking in positive and/or social situations) was the most tightly associated with the outcome. The repeated measures and mediation analyses suggest that favorable changes in this measure over time, which was most pronounced in the PSF condition, were predictive of abstinence. These findings are consistent with results reported by 3 other groups in diverse US PLWH populations.26,35,36 Decisional balance, which is an assessment of positive (eg, “Smoking cigarettes relieves tension”) and negative (eg, “My cigarette smoking bothers other people”) aspects of smoking, also influences smoking behaviors.14 Similar to Stanton et al,26 we found that a lower assessment of the importance of the positive aspects of smoking was associated with abstinence. Program content meant to reduce positive views of smoking and increase negative views should be included and emphasized in cessation programs targeting PLWH. Finally, the subjects with lower loneliness scores were more likely to quit smoking. Loneliness is associated with higher rates of tobacco use.37 In our study, this finding did not seem to be a surrogate for social support or depression because our measures of social support and depression were not associated with the outcome. Loneliness is associated with other social realities, such as stigmatization, discrimination, and boredom, which are all related to tobacco use.38,39 It is noteworthy that the most highly rated aspects of the PSF program were those related to the social aspects of the group intervention. This is an observation worthy of additional study.
The PSF program emphasized the potential role of buddies in the quitting process. However, only 3 subjects brought buddies to the sessions, and the buddy component of PSF was rated as among the least helpful by subjects in their program evaluations. These disappointing findings suggest that buddies may not be the optimal agents of social support in cessation interventions for PLWH smokers.
The study had several limitations worthy of mention. The 3-month cessation endpoint is appropriate for a pilot trial, but more definitive work will require 6- or 12-month abstinence data.40 Seven-day point-prevalence abstinence is a standard tobacco treatment outcome that has been closely correlated with 6-month continuous abstinence in prior large studies.41 Although the trial was powered to evaluate the efficacy of the PSF intervention, the relatively small sample size may have limited its ability to assess relationships between the range of sociobehavioral data collected and study outcomes. In the PSF condition, >13% of subjects failed to attend even a single program session and thus received no dose of the intervention. The group cessation program was associated with significant costs, in terms of labor, time, and space, beyond those of less intensive interventions. As the medical community gains knowledge about the most effective approaches to tobacco treatment in PLWH, cost–benefit analyses will be a necessary component of future public health decisions in this area. Finally, our study was limited to PLWH smokers who were motivated to quit in single center. Although our clinic population is sociodemographically typical of inner city HIV-care clinics throughout the country, our findings may not be generalizable to patients elsewhere nor to HIV-infected smokers who are less motivated to quit.
In conclusion, PSF, a group-therapy intervention targeting PLWH smokers, seemed to be effective in promoting smoking cessation. Elements of the program that received the highest praise were the group dynamic, the inclusion of an HIV-infected coleader, and the HIV-referent material presented in the curriculum. High session attendance rates, although difficult to achieve, were an important factor in program success. African American PLWH smokers were less likely to achieve abstinence, suggesting that this group requires additional or more intensive treatment strategies. Findings relating to loneliness and prosmoking decisional balance should be considered in the design of future interventions. Multiple studies, including ours, have now shown self-efficacy, especially in positive affect and social situations, to be a critical determinant of program success. Measures to increase self-efficacy should be incorporated into all tobacco treatment efforts targeting PLWH smokers.
The authors gratefully acknowledge the assistance of Ms. Kerry Poeggel, Mr. Scott Lloyd, Ms. Daniela Morales, Ms. Rebecca Herskovits, Moonseong Heo, PhD, the Montefiore Medical Center Infectious Diseases Clinic Community Advisory Board, and all of the study participants.
1. Reynolds NR. Cigarette smoking and HIV: more evidence for action. AIDS Educ Prev. 2009;21:S106–S121.
2. Tesoriero JM, Gieryic SM, Carrascal A, et al.. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav. 2010;14:824–835.
3. Shiels MS, Pfeiffer RM, Gail MH, et al.. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst. 2011;103:753–762.
4. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003.
5. Miguez-Burbano MJ, Burbano Z, Ashkin D, et al.. Impact of tobacco use on the development of opportunistic respiratory infections in HIV seropositive patients on antiretroviral therapy. Addict Biol. 2003;8:39–43.
6. Crothers K, Griffith T, McGinnis KA, et al.. The impact of cigarette smoking on mortality, quality of life, and comorbid illness among HIV-positive veterans. J Gen Intern Med. 2005;20:1142–1145.
7. Shuter J, Bernstein SL. Cigarette smoking is an independent predictor of non-adherence in HIV-infected individuals receiving highly active antiretroviral therapy. Nicotine Tob Res. 2008;10:731–736.
8. Lifson AR, Neuhaus J, Arribas JR, et al.. Smoking-related health risks among persons with HIV in the strategies for management of antiretroviral therapy clinical trial. Am J Public Health. 2010;100:1896–1903.
9. Shuter J, Bernstein SL, Moadel AB. Cigarette smoking behaviors and beliefs in persons living with HIV/AIDS. Am J Health Behav. 2012;36:75–85.
10. Riley ED, Gandhi M, Hare C, et al.. Poverty, unstable housing, and HIV infection among women living in the United States. Curr HIV/AIDS Rep. 2007;4:181–186.
11. Boarts JM, Bogart LM, Tabak MA, et al.. Relationship of race-, sexual orientation-, and HIV-related discrimination with adherence to HIV treatment: a pilot study. J Behav Med. 2008;31:445–451.
12. Bogart LM, Cogwill BO, Kennedy D, et al.. HIV-related stigma among people with HIV and their families: a qualitative analysis. AIDS Behav. 2008;12:244–254.
13. Reynolds NR, Neidig JL, Wewers ME. Illness representation and smoking behavior: a focus group study of HIV-positive men. J Assoc Nurses AIDS Care. 2004;15:38–46.
14. Abrams DB, Niaura R, Brown RA, et al.. The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. New York, NY: Guilford Press; 2003.
15. Wewers ME, Neidig JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. J Assoc Nurses AIDS Care. 2000:11:37–44.
16. Vidrine DJ, Arduino RC, Lazev AB, et al.. A randomized trial of a proactive cellular telephone intervention for smokers living with HIV/AIDS. AIDS. 2006;20:253–260.
17. Vidrine DJ, Marks RM, Arduino RC, et al.. Efficacy of cell phone-delivered smoking cessation counseling for persons living with HIV/AIDS: 3-month outcomes. Nicotine Tob Res. 2012;14:106–110.
18. Lloyd-Richardson EE, Stanton CA, Papandonatos GE, et al.. Motivation and patch treatment for HIV+ smokers: a randomized clinical trial. Addiction. 2009;104:1891–1900.
20. Abrams DB, Biener L. Motivational characteristics of smokers at the workplace: a public health challenge. Prev Med. 1992;21:679–687.
21. Bandura A. Health promotion by social cognitive means. Health Educ Behav. 2004;31:143–164.
22. Fagerstrom KO, Schneider NG. Measuring nicotine dependence: a review of the Fagerstrom Tolerance Questionnaire. J Behav Med. 1989;12:159–182.
23. Curry S, Wagner EH, Grothaus LC. Intrinsic and extrinsic motivation for smoking cessation. J Consult Clin Psychol. 1990;58:310–316.
24. Mermelstein R, Shadel WG. Individual differences in self-concept among smokers attempting to quit: validation and predictive utility of measures of the smoker self-concept and abstainer self-concept. Ann Behav Med. 1996;18:151–156.
25. Velicer WF, DiClemente C, Rossi JS, et al.. Relapse situations and self-efficacy: an integrative model. Addict Behav. 1990;15:271–283.
26. Stanton CA, Lloyd-Richardson EE, Papandonatos GD, et al.. Mediators of the relationship between nicotine replacement therapy and smoking abstinence among people living with HIV/AIDS. AIDS Educ Prev. 2009;21:63–78.
27. Mermelstein R, Cohen S, Lichtenstein E, et al.. Social support and smoking cessation and maintenance. J Consult Clin Psychol. 1986;54:447–453.
28. Ironson G, Solomon GF, Balbin EG, et al.. Ironson–Woods Spirituality/Religiousness index is associated with long survival, health behaviors, less distress, and low cortisol in people with HIV/AIDS. Ann Behav Med. 2002;24:34–48.
29. Russell D. The UCLA Loneliness Scale (Version 3): reliability, validity, and factor structure. J Pers Assess. 1996;66:20–40.
30. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas. 1977;1:385–401.
31. Savard J, Laberge B, Gauthier JG, et al.. Evaluating anxiety and depression in HIV-infected patients. J Pers Assess. 1998;71:349–367.
32. U.S. Department of Health and Human Services. Treating Tobacco Use and Dependence. Rockville, MD: Public Health Service; 2000.
33. Brown RA, Kahler CW, Niaura R, et al.. Cognitive-behavioral treatment for depression in smoking cessation. J Consult Clin Psychol. 2001;69:471–480.
34. Trinidad DR, Perez-Stable EJ, White MM, et al.. A nationwide analysis of US racial/ethnic disparities in smoking behaviors, smoking cessation, and cessation-related factors. Am J Public Health. 2011;101:699–706.
35. Vidrine DJ, Arduino RC, Gritz ER. Impact of a cell phone intervention on mediating mechanisms of smoking cessation in individuals living with HIV/AIDS. Nicotine Tob Res. 2006;8:S103–S108.
36. Ingersoll KS, Cropsey KL, Heckman CJ. A test of motivational plus nicotine replacement interventions in HIV positive smokers. AIDS Behav. 2009;13:545–554.
37. Lauder W, Mummery K, Jones M, et al.. A comparison of health behaviors in lonely and non-lonely populations. Psychol Health Med. 2006;11:233–245.
38. Herskovits R, Knackmuhs E, Stanton C, et al.. The relationship between perceived racism/discrimination and smoking habits in persons living with HIV and AIDS. Presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 17–20, 2011; Rome, Italy.
39. Peretti-Watel P, Constance J. “It's all we got left.” Why poor smokers are less sensitive to cigarette price increases. Int J Environ Res Public Health. 2009;6:608–621.
40. Hughes JR, Keely JP, Niaura RS, et al.. Measures of abstinence in clinical trials: issues and recommendations. Nicotine Tob Res. 2003;5:13–25.
41. Velicer WF, Prochaska JO. A comparison of four self-report smoking cessation outcome measures. Addict Behav. 2004;29:51–60.
© 2012 Lippincott Williams & Wilkins, Inc.